You are here:
lidocaine 5% medicated plaster (Versatis)
Advice
Following a resubmission
lidocaine 5% medicated plaster (Versatis®) is accepted for restricted use within NHS Scotland for the treatment of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia).
There are only limited comparative data available for lidocaine plasters, the comparative clinical effectiveness remains unclear. It is restricted to use in patients who are intolerant of first-line systemic therapies for post-herpetic neuralgia or where these therapies have been ineffective.
Drug Details
| Drug Name: | lidocaine 5% medicated plaster (Versatis) |
|---|---|
| SMC Drug ID: | 334/06 |
| Manufacturer: | Grünenthal Ltd |
| Indication: | Treatment of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN) |
| BNF Category: | |
| Sub Category: | 15.2 Local anaesthesia |
| Submission Type: | Resubmission |
| Status: | Restricted |
| Date Advice Published: | 11 August 2008 |
Archived Advice
| lidocaine 5% medicated plaster (Versatis®) (334/06) | Full submission | 12 March 2007 |